Loading company…
selectION, Inc. is a San Diego biotech developing drugs for autoimmune diseases, led by si-544, a Kv1.3 ion channel blocker.
Founded in 2017 and headquartered in San Diego, US, selectION, Inc. develops pharmaceuticals for autoimmune conditions and ion channel disorders. Its lead product, si-544, targets T-cell mediated autoimmunity and is aimed at conditions such as psoriasis vulgaris and psoriatic arthritis. The company raised USD 5.06 mn in a Series A round on April 1, 2021, at a current valuation of USD 27.52 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in